Madrigal Pharmaceuticals Inc (MDGL)
204.65
-13.73
(-6.29%)
USD |
NASDAQ |
Apr 24, 16:00
204.69
+0.04
(+0.02%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (Quarterly): 70.64M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 70.64M |
| September 30, 2023 | 70.95M |
| June 30, 2023 | 68.60M |
| March 31, 2023 | 62.15M |
| December 31, 2022 | 70.74M |
| September 30, 2022 | 68.27M |
| June 30, 2022 | 58.50M |
| March 31, 2022 | 47.93M |
| December 31, 2021 | 52.89M |
| September 30, 2021 | 54.87M |
| June 30, 2021 | 51.63M |
| March 31, 2021 | 45.77M |
| December 31, 2020 | 53.43M |
| September 30, 2020 | 53.29M |
| June 30, 2020 | 44.69M |
| March 31, 2020 | 33.40M |
| December 31, 2019 | 24.91M |
| September 30, 2019 | 19.45M |
| June 30, 2019 | 15.59M |
| March 31, 2019 | 12.37M |
| December 31, 2018 | 8.871M |
| September 30, 2018 | 6.211M |
| June 30, 2018 | 5.109M |
| March 31, 2018 | 5.198M |
| December 31, 2017 | 6.512M |
| Date | Value |
|---|---|
| September 30, 2017 | 6.682M |
| June 30, 2017 | 6.816M |
| March 31, 2017 | 4.38M |
| December 31, 2016 | 5.523M |
| September 30, 2016 | 7.806M |
| June 30, 2016 | 2.088M |
| March 31, 2016 | 0.516M |
| December 31, 2015 | 0.7732M |
| September 30, 2015 | 0.6826M |
| June 30, 2015 | 16.38M |
| March 31, 2015 | 16.18M |
| December 31, 2014 | 15.65M |
| September 30, 2014 | 16.21M |
| June 30, 2014 | 18.76M |
| March 31, 2014 | 17.58M |
| December 31, 2013 | 19.98M |
| September 30, 2013 | 17.62M |
| June 30, 2013 | 17.88M |
| March 31, 2013 | 16.38M |
| December 31, 2012 | 14.35M |
| September 30, 2012 | 11.74M |
| June 30, 2012 | 11.25M |
| March 31, 2012 | 12.07M |
| December 31, 2011 | 10.86M |
| September 30, 2011 | 10.75M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
15.59M
Minimum
Jun 2019
70.95M
Maximum
Sep 2023
50.93M
Average
53.29M
Median
Sep 2020
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.563B |
| Viking Therapeutics Inc | 20.50M |
| Akero Therapeutics Inc | 53.39M |
| 89bio Inc | 33.59M |
| Geron Corp | 32.91M |